These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 28555422

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Surgery for Recurrent High-Grade Glioma After Treatment with Bevacizumab.
    Blumenthal DT, Kanner AA, Aizenstein O, Cagnano E, Greenberg A, Hershkovitz D, Ram Z, Bokstein F.
    World Neurosurg; 2018 Feb; 110():e727-e737. PubMed ID: 29183864
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy.
    Fraum TJ, Kreisl TN, Sul J, Fine HA, Iwamoto FM.
    J Neurooncol; 2011 Nov; 105(2):281-9. PubMed ID: 21603965
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Baseline multicentric tumors, distant recurrences and leptomeningeal dissemination predict poor survival in patients with recurrent glioblastomas receiving bevacizumab.
    Toh CH, Liau CT, Wei KC, Castillo M.
    J Neurooncol; 2019 Mar; 142(1):149-159. PubMed ID: 30535596
    [Abstract] [Full Text] [Related]

  • 8. Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology.
    Pasqualetti F, Pace A, Gonnelli A, Villani V, Cantarella M, Delishaj D, Vivaldi C, Molinari A, Montrone S, Pellerino A, Franchino F, Baldaccini D, Lombardi G, Lolli I, Catania F, Bazzoli E, Morganti R, Fabi A, Zagonel V, Bocci G, Fabrini MG, Rudà R, Soffietti R, Paiar F.
    Am J Clin Oncol; 2018 Dec; 41(12):1272-1275. PubMed ID: 29782366
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab.
    Di Stefano AL, Labussiere M, Lombardi G, Eoli M, Bianchessi D, Pasqualetti F, Farina P, Cuzzubbo S, Gallego-Perez-Larraya J, Boisselier B, Ducray F, Cheneau C, Moglia A, Finocchiaro G, Marie Y, Rahimian A, Hoang-Xuan K, Delattre JY, Mokhtari K, Sanson M.
    J Neurooncol; 2015 Feb; 121(3):499-504. PubMed ID: 25488073
    [Abstract] [Full Text] [Related]

  • 11. Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab.
    Leu K, Boxerman JL, Lai A, Nghiemphu PL, Pope WB, Cloughesy TF, Ellingson BM.
    J Magn Reson Imaging; 2016 Nov; 44(5):1229-1237. PubMed ID: 26971534
    [Abstract] [Full Text] [Related]

  • 12. The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter?
    Blumenthal DT, Mendel L, Bokstein F.
    J Neurooncol; 2016 May; 127(3):493-502. PubMed ID: 26721244
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Treatment of recurrent glioblastoma with single-agent bevacizumab].
    Sinkó D, Nemeskéri C.
    Orv Hetil; 2016 Mar 27; 157(13):500-3. PubMed ID: 26996897
    [Abstract] [Full Text] [Related]

  • 15. Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab.
    Manneh Kopp RA, Sepúlveda-Sánchez JM, Ruano Y, Toldos O, Pérez Núñez A, Cantero D, Hilario A, Ramos A, de Velasco G, Sánchez-Gómez P, Hernández-Laín A.
    Clin Transl Oncol; 2019 Oct 27; 21(10):1413-1423. PubMed ID: 30877636
    [Abstract] [Full Text] [Related]

  • 16. ADC quantification to classify patients candidate to receive bevacizumab treatment for recurrent glioblastoma.
    Asenjo García B, Navarro Guirado F, Nagib Raya F, Vidal Denis M, Bravo Rodríguez F, Galán Montenegro P.
    Acta Radiol; 2020 Mar 27; 61(3):404-413. PubMed ID: 31357873
    [No Abstract] [Full Text] [Related]

  • 17. Phospholipid metabolites in recurrent glioblastoma: in vivo markers detect different tumor phenotypes before and under antiangiogenic therapy.
    Hattingen E, Bähr O, Rieger J, Blasel S, Steinbach J, Pilatus U.
    PLoS One; 2013 Mar 27; 8(3):e56439. PubMed ID: 23520454
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.